Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2025)

Historic Operating Leases for Zevra Therapeutics (ZVRA) over the last 7 years, with Q3 2025 value amounting to $1.4 million.

  • Zevra Therapeutics' Operating Leases rose 19130.43% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 19130.43%. This contributed to the annual value of $792000.0 for FY2024, which is 7368.42% up from last year.
  • Per Zevra Therapeutics' latest filing, its Operating Leases stood at $1.4 million for Q3 2025, which was up 19130.43% from $1.6 million recorded in Q2 2025.
  • Zevra Therapeutics' Operating Leases' 5-year high stood at $1.8 million during Q2 2021, with a 5-year trough of $456000.0 in Q4 2023.
  • In the last 5 years, Zevra Therapeutics' Operating Leases had a median value of $1.1 million in 2022 and averaged $1.1 million.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 6553.29% in 2023, then skyrocketed by 19130.43% in 2025.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Operating Leases stood at $1.6 million in 2021, then fell by 16.69% to $1.3 million in 2022, then tumbled by 65.53% to $456000.0 in 2023, then surged by 73.68% to $792000.0 in 2024, then skyrocketed by 77.65% to $1.4 million in 2025.
  • Its last three reported values are $1.4 million in Q3 2025, $1.6 million for Q2 2025, and $1.2 million during Q1 2025.